Archives des World-Leading Research | Page 5 of 8 | The Ottawa Hospital Foundation

Read about our projects

As our researchers move new research projects forward faster than ever in an effort to address COVID-19, donations to the COVID-19 Emergency Response Fund continue to provide seed funding to get these vital projects off the ground. Below are some of the new and promising projects approved for support through the second round of funding. Kick-starting these projects would not have been possible without the support of our generous donors — thank you!

Harnessing cancer-fighting viruses to develop a COVID-19 vaccine

Drs. Carolina Ilkow, John Bell and colleagues are harnessing their expertise in making oncolytic (cancer-fighting) viruses to develop a vaccine against COVID-19, in partnership with scientists and clinicians in Canada and around the world. One of the key things they’ve learned is that the best cancer-killing viruses also stimulate the body’s own immune system – in effect, training the immune cells to recognize and help attack the cancer cells.

They have developed a number of viruses that are very good at boosting the immune system and have already been tested safely in people. These viruses will be reengineered by splicing in key genes from the COVID-19 virus to create several candidate vaccines, which would train the body to mount an immune response against COVID-19. They expect this live vaccine will be particularly important for healthcare workers and vulnerable populations, including people with cancer. Once the vaccine is created, large quantities can be made in The Ottawa Hospital’s Biotherapeutics Manufacturing Centre.

“We know that people with cancer who get COVID-19 are much more likely to get severely ill, so we think that working on a vaccine is the best thing we can do right now to help cancer patients.”
– Dr. John Bell

UPDATE:
The research team has developed candidate vaccines and laboratory testing is going well. With funding, the team will be ready to do human clinical trials in the new year.

Creating a new mouse model to study COVID-19 lung disease

Drs. Manoj Lalu, Duncan Stewart and colleagues are working to develop a mouse model of COVID-19 that mimics the severe lung disease seen in humans.

The lack of good, accessible animal models of this disease is severely limiting research around the world. The COVID-19 virus doesn’t infect regular lab mice very well, and the virus is dangerous to work with because it is so contagious for humans.

Drs. Lalu are Stewart are working with Drs. Carolina Ilkow and John Bell, who are creating a novel hybrid virus that features a key protein from the COVID-19 virus (the spike protein) embedded into a well-studied and safe virus called vesicular stomatitis virus (VSV).

The team will test this hybrid virus in mice that have been genetically engineered to be more susceptible to COVID-19, to mimic the severe lung disease seen in humans.

To make sure the model is accurate, they will use sophisticated techniques to compare their findings in mice with findings from patients, focusing on effects on the lungs, blood and blood vessels. They will then use this model to test new therapies, including mesenchymal stromal cells.

UPDATE:
A novel hybrid virus (VSV-Cov2-S) has been manufactured by Dr. Ilkow’s lab with high quality and concentration to proceed with testing in our mouse model. Our experts have worked with the uOttawa Animal Care Committee and have successfully obtained ethics approval. Researchers began challenging ACE2 transgenic mice with the virus in December, controlling for time and dose, and assessing lung injury outcomes.

Studying the immune response of COVID-19 patients in the ICU

Why do some people get severely ill and die of COVID-19, while others experience only mild symptoms? Part of the answer may lie in how an individual’s immune system reacts (and sometimes over-reacts) to the COVID-19 virus. Dr. Shirley Mei and her intensive care research colleagues will study this in critically ill COVID-19 patients using the world’s most advanced “single-cell proteomics” technology.

This technology, called CyTOF, will allow the researchers to study up to 60 different biological factors all at the same time from one single cell. The researchers will create a multi-dimensional map of the immune response to COVID-19, showing how it changes over time and how it sometimes goes out of control.

The data will be shared with clinicians and researchers around the world, in order to improve treatment of COVID-19 and save lives.

UPDATE:
Patients participating in this research study will have blood samples taken for a period of 15 days after their enrollment and consent to participate. With approval from the research ethical board, researchers are in the process of recruiting patients into four arms of our study: septic patients in ICU (control cohort), COVID-19 patients in ward (mild disease cohort), ICU patients with severe COVID-19 (severe disease cohort), as well as healthy volunteer (healthy cohort). To date, 34 patients have been recruited with a total of 147 blood samples collected. Pilot experiments to validate the customized immune profiling panel for the mass cytometry (CyTOF) experiment have been completed. This approach will allow researchers to assess the disease progression by using the world’s most advance single-cell proteomics technology.

A balancing act: how to provide regular patient care amid the threat of COVID-19

Dr. Kednapa Thavorn and colleagues will use health administrative data from across Ontario, available through IC/ES, to model the risks of various scenarios for restarting routine clinical procedures in hospitals. Ontario hospitals have postponed many routine clinical procedures in order to preserve resources for COVID-19 patients, but these routine procedures can’t be postponed forever without serious health consequences.

As hospitals contemplate re-staring some routine care, a careful balance will need to be struck between the risks of COVID-19 and the risks of all other preventable diseases and conditions. The model will estimate overall deaths, healthcare costs and other factors for several scenarios, in order to help hospital administrators and policy makers make evidence-based decisions. The model could be adapted for different regions and for different COVID-19 scenarios, including a possible second wave.

UPDATE:
Researchers working on this project have developed a detailed protocol of the study and a model structure for a resource optimization model. They have requested the hospital data required for the model and expect to receive this information in January.

Helping COVID-19 survivors stay healthy

Drs. Sara J. Abdallah and Juthaporn Cowan

Drs. Sara J. Abdallah, Juthaporn Cowan and colleagues will study the long-term effects of COVID-19 in survivors, checking in on them three, six and 12 months after they were initially infected. While researchers are beginning to understand what happens in the body during a severe COVID-19 infection, much less is known about the long-term effects in survivors. But based on what is known about other viral infections, the long-term effects could be serious, affecting the lungs, heart and muscles, as well as mental health. Survivors of mild, moderate and severe infections will be included in the study. The researchers will also assess the healthcare resources used by survivors. Results will help improve care for COVID-19 survivors and optimize how healthcare resources are used.

UPDATE:
With support from The Ottawa Hospital COVID-19 Emergency Response Fund, researchers set out to understand the medium and long-term impact of COVID-19 on overall health. As of October 31, 2020, 64 enrolled participants completed comprehensive cardiopulmonary testing and important progress has been made in understanding the residual effects of COVID-19 on heart and lung function. As patients continue to be monitored at six and 12-months after COVID-19 infection, our researchers hope that their findings will inform future management strategies for post-COVID breathlessness.

World-first clinical trial aims to protect cancer patients from COVID-19

Dr. Rebecca Auer speaks with a colleague (Photo taken before COVID-19)

Surgeon-scientist Dr. Rebecca Auer is leading a world-first clinical trial that she hopes will protect cancer patients from COVID-19 and other respiratory infections by boosting their immune systems during treatment.

In collaboration with scientists at the Ontario Institute of Cancer Research, researchers will explore an immune-stimulator called IMM-101. The trial will be designed and run by the Canadian Cancer Trials Group at Queen’s University at nine cancer centres across Canada and will recruit 1,500 patients currently receiving cancer treatment.

This trial takes advantage of a lesser-known aspect of the immune system — innate immunity. This first-response arm of the immune system plays a key role in detecting viruses. The research team hopes the IMM-101 treatment will train the patient’s innate immune system to fight off the COVID-19 virus, in addition to other viruses that cause respiratory infections.

The advantage of this immune-boosting approach is that it could help cancer patients fight off all sorts of viruses while they are undergoing cancer treatments and are at their most vulnerable.

The trial has been approved by Health Canada and will run this summer and into the fall. Researchers expect to see preliminary results in about nine months.

UPDATE:
The clinical trial was activated in September and is now open in Ottawa for recruitment. The trial will enroll 1,500 patients across Canada, with approximately 200 patients from Ottawa. These Ottawa patients will be part of the translational study funded in part by the COVID-19 Emergency Response Fund.

“While there are many specific vaccines for COVID-19 in the works, they won’t be available for at least a year. Cancer patients need protection now.”
– Dr. Rebecca Auer

Support future projects

The COVID-19 research taking place at The Ottawa Hospital has the potential to transform our understanding of this virus and lead to new ways to prevent and treat it and save lives. This vital research is possible thanks to support from the community. Please consider giving today in support of the COVID-19 Emergency Response Fund.

To find out more about our COVID-19 research and the many collaborators working to make these projects happen, please visit The Ottawa Hospital’s Research Institute.

Keep checking back for more updates on how donations are being put to work right away and are making a difference in The Ottawa Hospital’s fight against COVID-19. To get regular updates sent directly to your inbox, sign up for our newsletter, Vital Links.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: COVID-19, COVID-19

Read about our projects

Using lab-grown human tissues to identify possible treatments
Stopping COVID-19 with behavioral science and artificial intelligence
Understanding the challenge of COVID-19 for Ottawa’s most vulnerable people
Mobile reporting of adverse events from a pandemic COVID-19 vaccine
Testing plasma from recovered COVID-19 patients as a possible treatment
Predicting COVID-19 in populations
Repurposing existing drugs and finding new ones

Solutions to some of our greatest healthcare challenges in the midst of the ever-changing COVID-19 pandemic, won’t come from one idea or one person. Innovation will come from a community of researchers, and academics, and also from front-line healthcare workers, support staff, volunteers and patients. To capture ideas for COVID-19 research and patient care innovations, The Ottawa Hospital responded quickly after the pandemic hit and launched the Ideas Hub, and it’s open to anyone at the hospital who has an idea to contribute— big or small. It is in large part thanks to donor support that we can accelerate the implementation of some of these creative ideas across our hospital.

Once ideas are submitted, within days they are triaged to expert teams assigned to evaluate the feasibility and potential impact of each. Coupled with the overwhelming support of our community, many will receive funding, and in turn, spark innovation at our hospital to help keep staff and patients safe as we continue to navigate the COVID-19 pandemic.

We are thrilled to announce that many of the ideas submitted are already underway at our hospital. Below are just a few of the exciting initiatives right here in Ottawa that will be receiving funding thanks to donor support of the COVID-19 Emergency Response Fund.

Using lab-grown human tissues to identify possible treatments

Dr. William Stanford and his colleagues are using human tissue models to understand why COVID-19 makes some patients severely ill. They also hope to identify and test new drugs that can reduce the severe lung damage that typically kills people with COVID-19. They will rapidly test two cellular pathways involved in causing this lung damage. They will then rapidly screen for drugs that have already been approved by Health Canada and the FDA that are able to block these pathways, and potentially reduce disease severity and death. Their research may also reveal biomarkers that can identify which patients with COVID-19 are most likely to require intensive care.

UPDATE:
Funding provided by the COVID-19 Emergency Response Fund was used to put another technician on this project. The research team is looking at acute kidney injury and renal failure in COVID-19 patients. It is highly debated among nephrologists whether the renal involvement is due to primary or secondary effects. Researchers on this project used stem cells to grow kidney-like tissues called organoids in the lab. Using this model, they found that certain parts of the kidney are readily infected by a hybrid virus that mimics COVID-19. These data suggest that the kidney disease experienced by COVID-19 patients is likely due to infection of the kidneys. The team is working with collaborators in Toronto to infect these human kidney organoids with live virus and analyze the impact of the infection.

Stopping COVID-19 with behavioral science and artificial intelligence

Dr. Justin Presseau and colleagues plan to use state-of-the-art behavioural science and artificial intelligence to develop an app that can help people reduce how much they touch their eyes, nose and mouth. This T-shaped area of the face known as the T-zone is the main way that the COVID-19 virus gets into the body. Reducing T-zone touching could reduce the transmission of COVID-19, as well as transmission of other infections that pass through the nose and mouth. Most people touch their T-zone 15-20 times per hour, often without realizing it.

The app would help people become aware of this behavior and walk them through possible techniques and training to reduce T-zone touching. This project will involve international experts in machine learning and computer vision, health psychology and behaviour change, and human-centred design and infection control.

UPDATE:
The research team led by The Ottawa Hospital and consisting of international experts in health psychology and implementation science are working on ways to support Canadians to reduce facial T-zone touching. They have identified several considerations that might influence this critical behaviour and the spread of disease. To coincide with flu season, they will be launching a national survey and conducting interviews with Canadians from coast to coast to improve their understanding of T-zone touching to inform the development of an additional protective strategy alongside physical distancing, handwashing, and wearing masks.

Understanding the challenge of COVID-19 for Ottawa’s most vulnerable people

Dr. Smita Pakhale and her colleagues will harness the trust and engagement they have built with Ottawa’s most marginalized communities over the last 10 years through community-based participatory action research to examine how COVID-19 has impacted these individuals. Marginalized people who are low-income, homeless, and at-risk of homelessness face numerous social and health inequities that are exacerbated by crises like the COVID-19 pandemic. These individuals face unique barriers when accessing health services and may be last in line for support. Data co-collected and co-analyzed with people of lived experience could lead to the development of better policies and programs to help vulnerable populations during COVID-19 and future crises.

UPDATE:
Since the funding announcement, researchers have completed the ethics approval process, and are now implementing the project at the Bridge Engagement Center (the Bridge), located in Vanier, Ottawa. The team is using a community-based participatory action research approach and have completed selection and training of community peer researchers with lived experience. These peer researchers have helped co-design surveys and interview guides. They are now actively recruiting project participants and collecting data at the Bridge via telephone, ensuring their safety. Preliminary findings are noteworthy, demonstrating more challenges faced by these most-marginalized communities as compared to pre-COVID-19. Researchers aim to complete the recruitment and data collection over the next few months which will also include semi-structured interviews about in-depth experiences during COVID-19, as well as a card-sorting exercise focused on COVID-19 media messaging. This approach ensures that those with limited literacy are still able to share their thoughts and experiences with the COVID-19 pandemic.

Mobile reporting of adverse events from a pandemic COVID-19 vaccine

Dr. Kumanan Wilson and his colleagues will harness their electronic vaccine-tracking platform CANImmunize to let Canadians report potential adverse events from a COVID-19 vaccine through their mobile device. This will be crucial in ensuring both the safety of a COVID-19 vaccine and enhancing public trust in the vaccine.

The team has already built and tested a proof-of-concept pilot app in partnership with the Canadian Vaccine Safety Network for monitoring adverse events from the seasonal influenza vaccine. This reporting function will be activated for testing during the fall flu season for use by participating employees at The Ottawa Hospital, in preparation for a probable COVID-19 vaccine in 2021.

UPDATE:
The app has been developed and the trial is underway. This project was featured on CTV National News in November.

Testing plasma from recovered COVID-19 patients as a possible treatment

Drs. Alan Tinmouth and Dean Fergusson are contributing to the global effort to determine if plasma from people who have recovered from COVID-19 (called convalescent plasma) could be an effective treatment for actively infected patients. When someone becomes infected with COVID-19, their immune system develops antibodies against the virus. After they have recovered, these antibodies remain present in their plasma to shield them from possible future infection.

In theory, these antibodies could be transfused into people with an active COVID-19 infection, to help them fight off the virus. The trial will be conducted by the Canadian Transfusion Research Network in collaboration with Canadian Blood Services and Hema-Québec who will collect and test convalescent plasma in adults (CONCOR-1 study) and children (CONCOR-Kids study).

UPDATE:
Proposed treatment: COVID-19 convalescent plasma (CCP) is the plasma collected from individuals who have previously contracted SARS-CoV-2 virus and COVID-19 disease and have developed neutralizing antibodies. The research team has partnered with Canadian Blood Services and Hema Quebec to solicit, collect, prepare and distribute CCP. This is a randomized clinical trial with 59 sites in Canada, three in New York City, one in Israel, and three in Brazil. The first patient was enrolled in May and there are now 425 patients enrolled with over 30 at our hospital. There have been no serious adverse events related to CCP reported to date and 2400 units have been collected and distributed across Canada. The trial will end in June 2021 and dissemination of results will happen in July 2021.

Predicting COVID-19 in populations

Dr. Doug Manuel and his colleagues in partnership with Ottawa Public Health have created an interactive website (613covid.ca) that predicts various scenarios around the number of hospitalizations and deaths in Ottawa due to COVID-19. The methods they are developing will help advance COVID-19 projections worldwide in addition to helping with local planning. They plan to refine their methods and develop better approaches to predict the effects of different levels of physical distancing. These projections will be invaluable in discussions around easing physical distancing restrictions.

UPDATE:
Funds for this project were used to run the 613covid.ca website. This research team is unique in Canada — and one of the few worldwide — to provide daily, automatically generated covid-19 projections. There have been over 100K views of the projections since it launched in the spring. The program has expanded to include:

long-term and short-term projections for cases and hospitalizations.
first-in-Canada wastewater surveillance and modelling.
SCRiPS – an online calculator that public health experts can use to help develop COVID-19 screening and testing protocols.

Repurposing existing drugs and finding new ones

Dr. Jean-Simon Diallo and his colleagues have developed a novel “bio-sensor” that can identify drugs that block the COVID-19 virus from attaching to cells, thereby preventing infection. First, they plan to test this novel approach on a library of more than 1,000 small molecules that have been approved to treat other diseases. Then they will attempt to identify novel antivirals drugs from a library of more than 200,000 small molecules.

UPDATE:
This project aims to identify antiviral drugs that can help in the fight against coronavirus. The research team has developed a novel biosensor allowing them to test the effects of hundreds of thousands of drugs in this capacity. The first step aimed to identify potential antivirals from a collection of over 1000 currently approved drugs that may be repurposed as antivirals. They have identified one leading candidate drug from this collection which is a common antifungal and that appears to block the interaction between SARS-CoV-2 and the protein to which it normally binds to enter and infect cells. The next steps are to directly test this drug on coronavirus through collaboration with other researchers in Canada and expand testing to a much larger collection of new potential drugs.

More inspiring projects

The projects currently underway are just the beginning. In the coming weeks, additional COVID-19 Emergency Response Fund grants will be awarded for research, as well as for the development of innovative treatments and creative new ways to combat the virus. But our work is not yet complete. We need donor support to ensure the COVID-19 Emergency Response Fund can continue to support front-line medical teams, provide essential equipment, and contribute to the care and comfort of patients.

To find out more about our research and the many collaborators working to make these projects happen, please visit The Ottawa Hospital’s Research Institute.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: COVID-19

APRIL 29, 2020 OTTAWA, ON – The Ottawa Hospital’s COVID-19 Emergency Response Fund received a significant boost thanks to the generosity of a $100,000 match gift from the Nanji Family Foundation.

“The Ottawa Hospital Foundation is incredibly grateful to have the support of the Nanji Family Foundation and we look forward to seeing how their gift will inspire others to give,” said Tim Kluke, President and CEO, The Ottawa Hospital Foundation.

The COVID-19 Emergency Response Fund will help patients and staff directly affected by the COVID-19 pandemic. Donations made will be matched by the Nanji Family Foundation and will:

support our frontline medical teams
purchase specialized protective equipment
develop innovative treatments through highly specialized technology
contribute to the care and comfort of patients
support our scientists and our researchers in their efforts to combat COVID-19

As the pandemic continues to evolve, incredible stories of generosity continue to emerge. Our front-line healthcare team has to adapt quickly and this match gift of up to $100,000 will help to keep them safe, along with our patients. It will also help support the work of our researchers who have joined the global fight against COVID-19. The Nanji Family Foundation has donated a total of $1.6 million to 16 hospitals across Canada in this collaborative effort.

We’re grateful to have the support from our community and thank the Nanji family for their leadership and for inspiring others to give and double their impact.

About The Ottawa Hospital:

The Ottawa Hospital is one of Canada’s top learning and research hospitals, where excellent care is inspired by research and driven by compassion. As the third-largest employer in Ottawa, our support staff, researchers, nurses, physicians, and volunteers never stop seeking solutions to the most complex healthcare challenges.

Our multi-campus hospital, affiliated with the University of Ottawa, attracts some of the most influential scientific minds from around the world. Our focus on learning and research leads to new techniques and discoveries that are adopted globally to improve patient care.

We are the Regional Trauma Centre for eastern Ontario and have been accredited with Exemplary Standing for healthcare delivery — the highest rating from Accreditation Canada. We are also home to world-leading research programs focused on cancer therapeutics, neuroscience, regenerative medicine, chronic disease, and practice-changing research.

Backed by generous support from the community, we are committed to providing the world-class, compassionate care we would want for our loved ones.

For more information about The Ottawa Hospital, visit ohfoundation.ca.

As the COVID-19 pandemic continues to evolve, experts at The Ottawa Hospital and healthcare partners throughout the region have geared up to stop the spread of this infectious disease. From our crisis preparedness plan, to COVID-19 research already underway, we have the knowledge and experience to tackle this pandemic head-on. Our researchers are harnessing their unique expertise and exploring more than 50 COVID-19 research projects to help in the global fight against this virus.

All of the COVID-19 simulation exercises and research projects being explored at The Ottawa Hospital will make use of shared research equipment, resources, and facilities that have been developed over many years, thanks to generous support from our community.

“Thanks to generous support from the community over the years, we’ve been able to develop unique research facilities and technologies that we are now rapidly applying to the fight against COVID-19,” said Dr. Duncan Stewart, Executive VP Research, The Ottawa Hospital. “Similarly, today’s community support for research means we will be ready for tomorrow’s health challenges, whatever they may be.”

Calming the immune system in critically ill patients

Dr. Stewart is leading a team of researchers working to launch a clinical trial of mesenchymal stromal cells (MSC) therapy for COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS).

The immune system plays a crucial role in defending the body against COVID-19, but sometimes it can become overactivated, resulting in severe damage to the lungs, called ARDS. In COVID-19 patients, ARDS is the major cause of severe illness and death.

Studies have shown that mesenchymal stromal cells (MSCs) can dampen an overactive immune response and help patients with ARDS related to other kinds of infections. Our researchers will build on their extensive experience in manufacturing MSCs and leading the world’s first clinical trial of MSCs for septic shock. This project will likely involve partners in Ontario and Europe, working in a concerted effort to find novel therapies to improve outcomes in COVID-19 patients.

Repurposing existing drugs and finding new ones

Researcher doing work in a laboratory. — *Dr. John Bell in his lab at The Ottawa Hospital. His team could use their virus manufacturing expertise in the production of a vaccine for COVID-19.*

Other researchers of The Ottawa Hospital and the University of Ottawa are looking to identify already-existing drugs and their potential effectiveness in treating patients with COVID-19. Drs. Taha Azad, Ragunath Singaravelu, Jean-Simon Diallo and John Bell have developed a novel system known as a bio-sensor that can identify small molecule drugs that block the COVID-19 virus from attaching to cells, thereby preventing infection. First, they plan to test this approach on a library of more than 1,000 small molecules that have been approved to treat other diseases. They will then attempt to identify antiviral drugs that could be effective in treating this virus.

Learning from our COVID-19 patients and testing therapies

Researchers from around the world are sharing their experiences and findings and are working together to determine the best approach to treating patients with COVID-19.

To help with this global effort, infectious disease researchers at The Ottawa Hospital and the University of Ottawa are working locally to create a registry of COVID-19 patients in our community. Under the leadership of Dr. Michaeline McGuinty and Dr. William Cameron, the researchers plan to look for patterns among cases and determine how well treatments are working. They will also use blood samples to study the virus and the body’s response to each treatment.

“Thanks to generous support from the community over the years, we’ve been able to develop unique research facilities and technologies that we are now rapidly applying to the fight against COVID-19.” – Dr. Duncan Stewart, senior scientist in the Regenerative Medicine Program and professor at the University of Ottawa

Working towards a vaccine

While some researchers work to find better treatment options for COVID-19, Dr. Carolina Ilkow, Dr. John Bell and their team of experts in making cancer-fighting viruses at The Ottawa Hospital are working hard to develop a possible vaccine, in partnership with scientists and clinicians in Canada and around the world. The vaccine would contain small parts of genetic material from the COVID-19 virus, embedded into a different virus that does not cause human disease. This replicating viral vaccine would also produce its own adjuvant – a substance that stimulates a stronger immune response, resulting in a more effective vaccine. Once a promising vaccine is created, the team will be able to make large quantities in The Ottawa Hospital’s Biotherapeutics Manufacturing Centre. This facility is the only hospital-based lab in Canada capable of producing virus-based vaccines and therapies for clinical trials.

*Nurses at the COVID-19 Assessment Centre prepare a swab to be transported to the lab and tested for COVID-19.*

Putting preparedness to the test

While our researchers have been nimble in responding to COVID-19 The Ottawa Hospital was already planning for the possibility of a future pandemic long before this virus appeared. When it comes to preparing for the worst, we are leading the way in developing strategies to effectively manage a crisis.

The intensive care units (ICU) at both the General and Civic campuses, where the most acutely ill COVID-19 patients will be treated, will triple their current size should we need the room. If these become over capacitated, the hospital would make use of other existing hospital facilities to increase its ability to care for severely ill patients.

Eastern Ontario hospitals are also working together to create a regional patient flow strategy to care for patients. Hospitals will transfer COVID-19 positive patients who need acute or critical care to select hospitals for treatment. Patients who do not require this level of care will be transferred out of acute or critical care hospitals to the most appropriate hospital setting. This will ensure that our healthcare system does not become overwhelmed by the COVID-19 outbreak.

Simulation exercises save lives

Transferring patients from the Emergency Department to the ICU is no easy feat in a 100-year-old hospital. It’s for this reason, the University of Ottawa Skills and Simulation Centre have readied staff by running simulation drills and tests.

The drills, which made use of a high-tech mannequin capable of sneezing, are designed to refine the safe treatment and transport of a severely-ill patient experiencing respiratory failure.

Simulations are vital as they allow staff to practice their skills in a real-time environment make adjustments if necessary, and ultimately provide better care to patients. Similar to the Code Orange simulations, which took place two months before the Westboro bus crash on January 11, 2019, this type of hands-on training further prepares staff on the frontlines.

On November 16, 2018, The Ottawa Hospital underwent a Code Orange emergency response exercise as part of ongoing preparedness to respond effectively to a disaster in the community. Participating in such a training exercise meant staff would be even more prepared should a real Code Orange be called.

Just two months later, a double-decker bus crashed into the Westboro bus station. Thirteen severely-injured patients were subsequently transported to the Emergency Department. The simulation exercise helped to ensure that The Ottawa Hospital staff were even more prepared to save their lives.

Community support essential

A strong hospital requires the support of its community and that couldn’t be more true than during these unprecedented times. You can support world-class care and ground-breaking research that is saving lives every day.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Biotherapeutics, TOH Family

Published: March 2024

Mackenzie Daybutch

Everyone deserves to feel a sense of belonging where they work, which is made so much easier when you feel a connection with others.

This is exactly the goal of The Ottawa Hospital’s Indigenous Employee Network (IEN). Created in October 2021, the IEN’s ongoing goal is to create a safe space for self-declared First Nations, Inuit and Métis employees at The Ottawa Hospital and their allies to connect, share experiences, and celebrate Indigenous culture.

Mackenzie Daybutch is Ojibway from Mississauga First Nation #8 in North-Eastern Ontario, where she is a status band member, Bear Clan, and inter-generational residential school survivor. She is the Program Coordinator for the Regional Indigenous Cancer Program at The Ottawa Hospital and is Lead of the IEN, which she describes it as a “sacred space where indigenous hospital employees and allies can connect.”

Learn more about Mackenzie and the critical work of the IEN.

Hélène Létourneau-Donnelly

Our hospital has seen its fair share of trailblazing women, and Hélène Létourneau-Donnelly deserves to be mentioned.

Her nursing career began at the then Ottawa General Hospital in 1959, where one week after graduating as an RN, she assumed the position of Assistant Director of Nursing. Only a few years later, her talents were recognized from across town and she became a director in nursing at the then Civic Hospital. She was a young woman who chose to follow her career aspirations of caring for others at a time when other women her age were getting married and having children. Hélène would be instrumental in leading that position for the next 27 years.

She’s recognized for developing and establishing, with the support of her committed staff, a list of major hospital programs. They include the Comprehensive Surgical Day Care, which was a first in Canada, Ottawa’s first Triage Nurse Program in the Emergency Department, the Cerebral Vascular Service and Poison Information Centre, also a first in Ottawa, and the city’s first Operating Room Technical Course.

She is respected for completing a PhD (Education), without thesis, on a part-time basis during this hectic time.

Whether it was advancing care for patients or her life-long commitment to the education and wellness needs of women, Hélène has routinely been a voice and passionate advocate for others.

Hélène’s actions and commitment to care at The Ottawa Hospital have long since continued into retirement as a volunteer and as a donor—she continues to find ways to give back. Hélène has been particularly interested in supporting women’s health through the Shirley E. Greenberg Women’s Health Centre and the Rose Ages Breast Health Centre, which has a room named after her.

Learn more about Hélène Létourneau-Donnelly.

Macrina Valcin

Last year, Registered Nurse Macrina Valcin wanted to find a creative way to mark Black History Month. With some help from her colleagues on the Mother Baby Unit at the General Campus, she transformed the unit’s bulletin board into a powerful celebration of the Black community, creating an intricate display with inspirational quotes, books to borrow and posters of historical Black leaders.

Macrina’s passion project was born from tragedy—the death of George Floyd. “I decided I was going to let people see what racism is, what Black culture is,” says Macrina. “I thought maybe they can see this display and learn a little bit more and ask me questions.”

This year, Macrina brought her creative labour of love to a much larger audience. Throughout all of February, Macrina’s displays were located in the Employee Corner right outside the cafeteria doors at both the General and Civic Campuses. The displays placed a strong focus on honouring Canadian Black heroes, including athletes, politicians and entrepreneurs.

There was also a collection of books and posters that commemorate Black leaders from the past. “One of my big goals with these displays is to honour the past and inspire the future,” says Macrina.

Macrina hopes her displays will spark some difficult but necessary reflections. “I think people forget that racism is everywhere and exists every day. I’m hoping that these displays will bring about a greater awareness of what people do not see and do not know.”

Read more about Macrina and how last year’s project led to her co-leading Black Community at The Ottawa Hospital.

Mary Ierullo

Mary Ierullo had her own children, but she was also the “other mother” to countless young women in Ottawa. After immigrating to Ottawa from Italy as a young girl in 1928, Mary was always inspired to help others.

In the 1950s, she saw young pregnant women from back home struggling, so, despite not holding an official role at the hospital, she helped set up the first prenatal clinic for immigrant women at the Civic Hospital. She held their hands, literally and figuratively, as they transitioned into motherhood in their new country.

Learn more about other amazing women like Mary in our 100 Moments series, celebrating the 100^th anniversary of the Civic.

Dr. Rebecca Auer

It was only a glimpse she caught, standing on the side of the Trans-Canada Highway as it curved along Lake Superior, but since then, Terry Fox has remained a source of inspiration for Dr. Rebecca Auer. His vision and determination helped motivate her to where she is today — an award-winning cancer clinician-scientist.

Dr. Auer combines revolutionary cancer research with hands-on patient care every day in her role as Executive Vice-President of Research and Innovation at The Ottawa Hospital and CEO and Scientific Director at The Ottawa Hospital Research Institute.

As a surgeon, Dr. Auer sees with clarity that, while surgery may be the best chance for a cure in most cancers, patients are particularly vulnerable to both infections and cancer recurrence in its aftermath, in large part because the immune system is suppressed in the postoperative period. Dr. Auer’s research program is focused on understanding the mechanisms behind this effect and reversing them with innovative therapies.

In recognition of her practice-changing research, Dr. Auer has been named the 2023 recipient of the Chrétien Researcher of the Year Award.

Learn about her childhood stint at CHEO and an alarming late night in the lab.

Marion Crowe

Access to culturally safe health care is a priority for The Ottawa Hospital. We’re focused on strengthening Indigenous partnerships to guide our work to improve the experiences of First Nation, Inuit and Métis patients and their families.  

TOH’s journey of reconciliation would not be possible without the vision of Marion Crowe – the first Indigenous Governor at TOH and Co-Chair of the Indigenous Peoples Advisory Circle.  An accomplished and award-winning leader in First Nations health equity and governance, Marion was appointed to the TOH board on Indigenous Peoples Day June 21, 2017.  She is also a proud member of Piapot First Nation in Saskatchewan and founding Chief Executive Officer of the First Nations Health Managers Association.   

Marion says TOH’s work to advance Indigenous priorities is a result of many candid and sometimes difficult conversations and a true willingness among everyone at the table to pursue the journey together. 

“The work of reconciliation is not easy,” she says. “You cannot have reconciliation without truth, and the truth can often times be painful and discouraging. With TOH, we’ve had a willingness from the beginning to engage in the hard work of reconciliation. We’ve created a true allyship at the leadership level and a real shift in thinking is gaining momentum across the organization. I commend the dedicated members of the Indigenous Peoples Advisory Circle for showing up for their people and for change. I’m immensely proud of our work together and look forward to continued progress.”

Read more about Marion Crowe and other incredible woman of our hospital by checking out our 100 Moments series, which shares extraordinary moments from the past century of the Civic.

Dr. Emily Gear

For decades, Dr. Emily Gear and her husband, Dr. Frank Berkman, a cardiologist at the Cardiac Unit (now called The University of Ottawa Heart Institute), lived across the street from the hospital so she could be at the Civic in minutes to deliver a baby. Dr. Gear had a practice in the basement of her home with a full-time nurse.   

“Her nurse was like another grandmother to us,” recalls Dr. Gear’s daughter, Janet Berkman. “She’d come up at noon and join us for lunch.”  

Janet also remembers many men over the years parked in the driveway of their home on Melrose Avenue, too uncomfortable to come inside with their wives.   

*Dr. Emily Gear was Ottawa’s first female OB/GYN, pictured here (front left) with a group of medical interns outside the Civic Hospital in 1950.*

“Mom loved the people at the Civic Hospital,” Janet adds. “She did rounds there every morning and was there all the time for deliveries. The Civic was almost like her second home.”

Read more about Dr. Gear and other incredible woman of our hospital by checking out our 100 Moments series, which shares extraordinary moments from the past century of the Civic.

Dr. Kathleen Gartke

*Dr. Gartke is the executive sponsor of the WPLC.*

“I spent more than 25 years as the only operating female orthopedic surgeon in the city. I know what it’s like not to feel like part of the group,” says Dr. Kathleen Gartke, Senior Medical Officer at The Ottawa Hospital.

Dr. Gartke’s sentiments are not unique among many women physicians. Although women have outnumbered men in medical school for 20 years, individual and systemic biases in healthcare can prevent qualified women candidates from pursuing, achieving and staying in leadership roles.

To fight this inequality, Dr. Virginia Roth, now The Ottawa Hospital’s Chief of Staff founded the Women Physician Leadership Committee (WPLC), formerly known as the Female Physician Leadership Committee, in 2011. It identifies, mentors and trains potential leaders, and recognizes, enables and supports existing leaders. A decade later, the committee is still going strong. The number of women division heads at the hospital grew from 12 percent in 2010 to 23 percent in 2021, an increase of 92 percent.

Read how the WPLC has made inroads for women physicians.

Dr. Julianna Tomlinson

Born, raised, educated, and trained in Ottawa, Dr. Julianna Tomlinson is using research to change the way we think about Parkinson’s disease. Her work focuses on Parkinson’s-linked genes and is revealing the complexity of the disease. As the Senior Laboratory Manager in Dr. Michael Schlossmacher’s lab at the Ottawa Hospital Research Institute (OHRI), Dr. Tomlinson is highly involved in community outreach, and her work is inspired and influenced by people living with Parkinson’s.

Read our Q&A with Dr. Tomlinson.

Dr. Barabara Vanderhyden

Dr. Barbara Vanderhyden has spent her career looking for the metaphorical missing pieces to some of ovarian cancer’s most complex puzzles. As a senior scientist at The Ottawa Hospital, professor at the University of Ottawa, and Corinne Boyer Chair in Ovarian Cancer Research, Dr. Vanderhyden’s work makes a 3,000-piece puzzle look like child’s play.

From her first award — the Soroptimist Award for her volunteering as a high schooler in 1978 — to the accolades she’s garnered since — including the Dr. J. David Grimes Research Career Achievement Award, the Capital Educator’s Award, and the Governor General’s Caring Canadian Award — Dr. Vanderhyden’s award-winning career has changed the way ovarian cancer is understood and treated today.

Learn why physiology is like a puzzle and why sucking eggs is a good thing in Dr. Vanderhyden’s lab.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Patient Care, TOH Family

A race against the clock

Karen Lawrence is no stranger to helping those in need. After all, she’s a Clinical Manager of Oncology at The Ottawa Hospital. Her position, largely characterized as providing specialized treatment and care to some of the hospital’s most ailing, has taught her the value of advocating for those in need and raising money for critical research.

Now, sitting with the knowledge that her own body will soon start to deteriorate, she reflects on her life – and the future of her three boys.

An uncertain future

On January 27, 2014, Karen received the results of a genetic test, confirming one of her biggest fears. She is a carrier of a gene that causes amyotrophic lateral sclerosis (ALS) – a rare disease that gradually paralyses people because their motor neurons, which send signals from the brain to the muscles, break down and die.

As she sits staring at an oversized clock mounted on her living room wall, it seems to take on more significance – each second that passes moves Karen toward her inevitable fate. Like so many family members before her, Karen will too develop the disease. It’s just a matter of time.

“My family has been stricken with the familial form of ALS,” she explains with a pained expression. “I have lost 14 members of my family to this devastating disease, including my father.”

Watching ALS render her father helpless, while keeping his mind intact, was a cruel reminder that today there is no fighting this disease. “There is little hope yet. Today, there is only pain and suffering. Facing an uncertain future, a cure can’t come soon enough,” says Karen.

Karen Lawrence sitting at the kitchen table in her home. — *Results of a genetic test showed Karen Lawrence carries a gene that causes ALS.*

Family ties

No one in Karen’s family realized it at the time. Several members of her extended family were diagnosed with ALS and passed before they connected the dots. It was only once her grandfather, uncle and father were diagnosed that the family started to talk about the fact that it was likely genetic. The women in her family, her aunt and cousins, were diagnosed in their 40’s. The men were diagnosed when they were a little older, but under the age of 60. Once diagnosed, most only survived 12-18 months.

With a 50/50 chance of having the gene, it was never far from Karen’s mind. “It’s like walking around with a target on your back. You’re just kind of waiting,” she said. And she was tired of it – the waiting. That’s when she got tested.

“It’s like walking around with a target on your back.” – Karen Lawrence

“When they told me I had the gene, I was very composed and held it together until I thought of my kids and then I started to cry. That’s when it really hit me. I potentially gave a terminal illness to my children. So that’s very difficult to live with.”

The race is on

When Karen found out that she had the gene, something as simple as dropping a pen, or a small stumble, would have her mind racing to the future.

Karen is aware that it’s just a matter of time before her brain will no longer be able to talk to her muscles. Eventually, she’ll have trouble with her balance, then she won’t be able to walk, then talk and then eat. But her mind will be intact, trapped within her body, while she waits for ALS to take her ability to breathe. Karen has a pretty clear idea of what this will look and feel like, having watched her father go through it just a few years ago.

So, how does she grapple with the thought of such a grim future? She runs – literally. And she raises a substantial amount of money in support of neuromuscular research and care while she’s at it.

Her first ever marathon was in Copenhagen and her second in New York City. More recently, she has participated in The Ottawa Hospital’s Run for a Reason, where alongside her team, she raised funds towards a brand-new Neuromuscular Centre right here in Ottawa.

“The race is on to fund research to find a cure, or to prevent onset before my three beautiful boys are faced with the same agonizing decision of whether to get tested.” – Karen Lawrence

Drs. Jodi Warman Chardon and Robin Parks were instrumental in establishing the NeuroMuscular Centre, which opened in 2018.

A new Neuromuscular Centre

Thousands of people in eastern Ontario are affected by neuromuscular diseases. Until recently, patients had to travel to Montreal or Toronto to participate in clinical trials to help further research in these diseases. However, Dr. Jodi Warman Chardon noted that The Ottawa Hospital had more than 50 researchers and clinicians working on behalf of people like Karen. Each is working on various aspects of neuromuscular disease – from clinical care to lab research. There was no reason why the most promising clinical trials couldn’t be offered here in Ottawa.

Dr. Warman teamed up with Senior Scientist Dr. Robin Parks, who is conducting lab-based research on neuromuscular diseases. Their dream to have a centre that would bring these experts together in one place caught traction, and in May 2018, The Ottawa Hospital Neuromuscular Centre opened its doors to patients. “What’s exciting is it’s more than just a clinic. It’s a clinical research centre,” said Dr. Robin Parks. “So the idea is to do research and get results that will then feed back to the patient to provide insight into new therapies for them.”

Today, Ottawa is at the global epicenter of neuromuscular research. Equipped with the strongest neuroscience research team in the world, we are well positioned to discover new treatment options and cures, which will change patient outcomes worldwide.

“When a cure is found for this disease [ALS], the chances are it will be found in Ottawa,” said Duncan Stewart, Executive Vice President, Research, The Ottawa Hospital.

Zest for life

Karen does not yet have ALS, so she is not undergoing any treatment. But she remains hopeful that when she develops the disease, she will participate in the Neuromuscular Centre’s clinical trials and benefit from treatment developed at The Ottawa Hospital.

Until then, she tries to not dwell on what lies ahead and instead focuses on her hope for a healthy future for her boys.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Clinical Trials

Hope despite aggressive skin cancer diagnosis

Diagnosed with a stage 4 melanoma at the age of 62, Dan Collins feared for his life when he learned about the aggressive form of cancer. However, immunotherapy treatment gave him a reason to hold out hope. Dan had hope because of scientists who never gave up; who were determined to turn the tables on cancer and to create a better chance of survival, for patients like him. Hope that a cure is coming.

Discovery of a mass

Four years ago, Dan had been travelling for work, when he started noticing some pain when he’d lean his head back to rest on the plane. He recalls turning to his family doctor to get answers. An ultrasound revealed there was something inside the back of his head that looked like a cyst.

After an initial biopsy, Dan was referred to a surgeon at The Ottawa Hospital Cancer Centre. Another biopsy revealed the cyst was actually a mass. It was melanoma. “I was scared. Cancer had stripped my family of so much. I lost both of my two older brothers and my father to cancer. I feared for my life,” recalls Dan.

Unfortunately, the mass starting growing – and it was growing fast. By the end of July, just two months later, the mass went from being not visible on the back of his head, to the size of a golf ball.

His surgical oncologist, Dr. Stephanie Obaseki-Johnson, initially wanted to shrink the tumour before surgery to remove it. However, the mass was growing too quickly.

Oncologist Dr. Michael Ong of The Ottawa Hospital in a patient room. — *Dan Collins with Oncologist Dr. Michael Ong.*

Time to act

On August 11, 2015, Dan had surgery that lasted most of the day. When it was over, he had 25 staples and 38 stitches in the back of his head. As he recovered, Dan was reminded of a saying that helped him through recovery, “Never be ashamed of your scars. It just means you were stronger than whatever tried to hurt you.”

He would need that strength with the news that awaited him. Only two weeks later, the mass was back. His doctors also discovered a mass in his right lung and shadows in the lining of his belly. He had stage 4 cancer – it had metastasized. This was an aggressive cancer that left Dan thinking about the family he had already lost and what would happen to him.

The next generation of treatment

Soon, he was introduced to The Ottawa Hospital’s Dr. Michael Ong and was told about immunotherapy – the next generation of treatment, with the hope of one day eliminating traditional and sometimes harsh treatment like chemotherapy. Dr. Ong prescribed four high doses of immunotherapy. At the same time, radiation treatment began for Dan – 22 in all. His immunotherapy treatments were three weeks apart at the Cancer Centre and between each, he would have an x-ray to monitor the tumours.

“Each x-ray showed the tumours were getting smaller. That’s when the fear started shifting to hope.” – Dan Collins, patient

By December 2015, Dan finished immunotherapy treatment and the next step was to wait. “This transformational treatment was designed to train my own immune system to attack the cancer. We would have to be patient to see if my system would do just that,” says Dan.

While the shadows in Dan’s stomach lining had shrunk, the mass in his lung had not. That’s when Dr. Ong prescribed another immunotherapy drug that would require 24 treatments.

Dan learned from his oncologist that melanoma has gone from being an extremely lethal cancer, with few treatment options, to having many different effective therapies available.

“When I started as an oncologist a decade ago, melanoma was essentially untreatable. Only 25 percent would survive a year. Yet now, we can expect over three quarters of patients to be alive at one year. Many patients are cured of their metastatic cancer and come off treatment. We are now able to prevent 50 percent of high-risk melanoma from returning because of advances in immunotherapy,” says Dr. Ong.

Dan completed his last immunotherapy treatments in September 2017.

Oncologist Dr. Michael Ong posing with armed crossed at The Ottawa Hospital. — *Oncologist Dr. Michael Ong of The Ottawa Hospital.*

Today, there is no sign of cancer

When Dan thinks back to the day of his diagnosis, he remembers wondering if he was going to die. “I believe I’m here today because of research and because of those who have donated to research before me.”

He thinks back to when his older brother Rick died of cancer in 2007. “At the time he was treated, his doctor asked if he would participate in a research study. The doctor told him directly, this would not help him, but it would help somebody in the future.” Dan pauses to reflect and then continues, “I like to think, that maybe, he had a hand in helping me out today. Maybe he helped me survive. One thing I do know is that research was a game changer for me.”

The Ottawa Hospital has been a leader in bringing immunotherapy to patients. Research and life-changing treatments available at The Ottawa Hospital altered Dan’s outcome and he hopes that advancements will continue to have an impact on many more patients, not only here at home but right around the world.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Cancer, Clinical Trials, Creating Tomorrow, Immunotherapy, Patient Care, Patient Care

Update: In early 2023, Dr. Thébaud’s team treated the first baby in their clinical trial that aims to prevent BPD in premature infants. This is the first trial of its kind in in the world. Read Dr. Thébaud’s Q&A to learn more about his critical work and what motivates him.

Published: August 2020

Little Olivia Eberts had oxygen tubes in her nose until after her first birthday. Because she was born prematurely, her tiny lungs were underdeveloped, and she couldn’t breathe without oxygen. Ironically for Olivia, and many premature babies like her, the oxygen that saved her life also damaged her lungs, causing bronchopulmonary dysplasia (BPD), which is like starting out life with emphysema. But a clinical trial at The Ottawa Hospital led by Dr. Bernard Thébaud, which uses stem cells to heal the lungs of premature babies, may be a game changer.

An unexpected early birth

Jamie Eberts was 22 weeks pregnant with twins when she started feeling some discomfort. She arrived at the General Campus of The Ottawa Hospital and was admitted — she was going into early labour.

Thankfully, the doctors and nurses at The Ottawa Hospital were ready for any scenario Jamie, her husband Tim, and the babies faced. Each day, there were gentle conversations about how the babies were doing, the process of delivering them, and the chances of survival. Every hour counted. Then, one of the babies developed an infection and all three lives were at risk — the babies had to be delivered.

Baby in NICU — Baby Olivia in the neonatal intensive care unit (NICU).

“Our babies, Liam and Olivia, were born at 5 a.m. on January 29, 2017, at 23-and-half-week’s gestation. Liam was born first. He was small, red, and didn’t make a sound,” remembers Jamie. Olivia weighed one pound, two ounces and Liam weighed only a few ounces more than she did. Both babies required oxygen and mechanical ventilation to keep them alive. As a result, both developed BPD — the most common cause of death in premature babies.

Sadly, baby Liam passed away a few weeks after he was born while Olivia remained in the Neonatal Intensive Care Unit (NICU) at The Ottawa Hospital for nine long months.

BPD in Canada

In Canada, 1,000 babies are diagnosed with BPD every year. Often, babies with BPD develop other chronic lung diseases, such as asthma, and many require prolonged oxygen and ventilation. Additionally, they have a high incidence of hospital readmissions in the first two years of life. Babies with BPD often have problems in other organs as well, such as the brain or the eyes.

When Olivia was finally discharged, she went home with an oxygen tank. During the first year of her life, Olivia spent more time in hospital than out.

“Even now, a simple flu that put me in bed for a couple of days put her in hospital and turns into pneumonia. It’s scary,” says Jamie. The doctor told her that with Olivia’s respiratory issues, she may require hospital intervention for the rest of her life.

Lack of treatment options

“Currently there is no treatment for this disease,” says Dr. Bernard Thébaud, a neonatologist and senior scientist at The Ottawa Hospital. With that being said, he’s determined to improve the outcome for babies, like Olivia, who have BPD.

 “In the laboratory, we discovered that a particular type of stem cell can prevent BPD or regenerate newborn lungs.”
— Dr. Bernard Thébaud

Read our Q&A with Dr. Bernard Thébaud

Dr. Bernard Thebaud, neonatal intensive care unit, The Ottawa Hospital — Dr. Bernard Thebaud in the neonatal intensive care unit (NICU) at The Ottawa Hospital.

“Our research uses stem cells, isolated from the umbilical cords of healthy newborns, to prevent the lung injury or even to some degree regenerate a damaged lung in the laboratory. We foresee that these stem cells, given during a certain time during the hospital stay of these babies, could prevent the progression of the lung disease.”

Unlike traditional stem cells that can directly replace damaged cells and tissues, the stem cells that Dr. Thébaud is studying work by producing healing factors that promote regeneration and repair.

Clinical trial offers hope

Dr. Thébaud and his research team have launched a phase I clinical trial to test the feasibility and safety of the stem cell treatment in premature babies. The team is doing everything in their power to make this clinical trial a success, including consulting with healthcare providers and parents of premature babies.

One thing they’ve learned from these consultations is that many parents don’t feel like they know enough about stem cells and clinical trials to decide if they want to enroll their child in the trial. So, Dr. Thébaud and his team created an animated video to explain these concepts and help parents make an informed decision. Parents can share the video with family members if they’d like a second opinion.

Jamie was involved in these consultations and her firsthand experience provided valuable insight to the research team as they planned this project. This is just one example of how researchers at The Ottawa Hospital are partnering with patients and caregivers to improve the quality and success of their research.

Dr. Bernard Thébaud looks at a premature baby in an isolette.

Dr. Thébaud and his team held a “dress rehearsal” for the clinical trial. “The dress rehearsal lets us test and tweak our tools for approaching parents, including the video, so we know what works best once we’re ready to begin offering the experimental treatment.”

If this initial trial is successful, Dr. Thébaud and his team will launch a larger Canadian clinical trial. “This is a critical step towards providing a potential breakthrough therapy that could help premature babies in Canada and around the world,” says Dr. Thébaud.

The made-in-Ottawa clinical trial is supported by The Ottawa Hospital’s Ottawa Methods Centre and Biotherapeutics Manufacturing Centre, and the Blueprint Translational Research Group.

First trial of its kind in Canada

“Stem cell research is incredibly innovative. Here, we have a very promising, emerging therapy that could prevent lung injury but also improve brain development and eyesight,” says Janet Brintnell, Clinical Manager of the NICU who has seen dozens of premature babies with BPD.

“It’s amazing when you think of what it may be able to do for the quality of life for the child, for their family, and for our healthcare system. It could reduce length of stay, hospital admissions, and improve long-term outcomes. It could help these little ones lead healthier lives.”
— Janet Brintnell

“We are the only ones doing this kind of stem cell research in Canada, and there are only a few other teams in the world that are doing this.”
— Dr. Bernard Thébaud

Yet, three years ago when Olivia was in the NICU, this treatment wasn’t yet available. Now, Jamie and Tim are self-described “cheerleaders” of Dr. Thébaud’s research and are hopeful for what it might mean for future preemies and their families.

“I believe this is our future,” says Jamie. “When I think about what this could have done for our family, I wonder if Liam could have possibly survived. Olivia may not be facing the delays she’s experiencing today. Even to this day, if we are asked to put Olivia in the trial as an older candidate, we will.”

Jamie also adds the there was an impact from a mental health and financial perspective. “Our oldest child, Jacob, has had a very unusual first four years of his life because of how adaptable he has had to be during these difficult times. As a family, this entire experience has been very challenging financially due to a variety of therapies for Olivia and having to get used to becoming a single income family for several years in order to manage Olivia’s complicated schedule. All of this could have potentially been avoided if Dr. Thébaud’s research were available to our twins.”

A new beginning

Olivia is now a happy, active toddler who loves copying what her older brother Jacob does. Although, she still has BPD, it is increasingly manageable, and she no longer requires supplemental oxygen. While Olivia may suffer respiratory illness her entire life, one day a stem cell treatment developed here in Ottawa could mean that the next generation of babies with BPD won’t.

Listen to Pulse Podcast and learn how one day stem cells could heal the lungs of premature babies with Dr. Bernard Thébaud and what it could mean for parents like Jamie Eberts.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Creating Tomorrow, NICU, Stem Cell

Could cancer biotherapeutics be the next revolution in cancer treatment?

From helping the body’s own immune system better detect and fight cancer, to treating cancer with genetically-enhanced immune cells, viruses and vaccines, The Ottawa Hospital is conducting cutting-edge research that could transform cancer care right here at home and around the world.

For decades, scientists have tried to stimulate the immune system to attack cancer cells. A breakthrough came through the discovery that cancer cells make key molecules that suppress immune cells and prevent them from attacking the cancer. This discovery opened the door to revolutionary immunotherapy drugs called checkpoint inhibitors, which have shown striking results in recent years.

While promising research on checkpoint inhibitors continues, the race is now on to bring an innovative new kind of immunotherapy to patients – one that uses living cells, viruses and genes to fight cancer.

The Ottawa Hospital is a world leader in developing these innovative therapies, called cancer biotherapeutics.

“Our immune system is constantly trying to recognize and kill cancer cells, but the cancer cells are always trying to hide from it.”
— Dr. John Bell

Helping the body recognize and destroy cancer

CAR T-cell therapy is an emerging biotherapeutic treatment that harnesses the power of a patient’s own immune cells, known as T-cells, to treat their cancer. T-cells play a critical role in the immune system by killing abnormal cells, such as cells infected by germs or cancer cells. In some cancers, like acute lymphoblastic leukemia (ALL), cancerous cells become invisible to the T-cells that are meant to kill them. In CAR-T therapy the T-cells are collected and reprogrammed in the lab to recognize and destroy the cancerous cells.

“This type of immunotherapy research is groundbreaking,” said Dr. Natasha Kekre, a hematologist and associate scientist at The Ottawa Hospital, “but it is important to remember that CAR-T therapy is still very new and there can be serious side effects. We need more research to learn about this therapy and make it work for even more people and more kinds of cancer.”

The Ottawa Hospital is one of the first hospitals in Canada to participate in internationally-led CAR-T trials, and as one of Canada’s top research and treatment centres, the hospital is ideally positioned to play a lead role in bringing an innovative CAR-T research program to Canada, and to Canadian patients.

“Our goal is to build Canadian expertise and capacity for innovation in the promising CAR-T field through both laboratory research and clinical trials,” said Dr. Kekre, who is working with a team across the country. “This could lead to better CAR-T therapies that work for more kinds of cancer, as well as innovative approaches for providing CAR-T therapy in the Canadian system.”

Infecting cancer cells with viruses

Another promising biotherapeutic treatment uses oncolytic viruses that selectively infect and kill cancer cells. “Our immune system is constantly trying to recognize and kill cancer cells, but the cancer cells are always trying to hide from it,” explained Dr. John Bell, senior scientist at The Ottawa Hospital. “When you infect a cancer cell with a virus, it raises a big red flag, which helps the immune system recognize and attack the cancer.”

Recent laboratory research from Dr. Bell’s team suggests that a combination of two immunotherapies, oncolytic viruses and checkpoint inhibitors, could be much more successful in treating breast cancer and possibly other cancers.

“We found that when you add a checkpoint inhibitor after the virus, this releases all the alarms and the immune system sends in the full army against the cancer,” said Dr. Bell.

Though these methods have shown promising results, more research and clinical trials are needed.

Cancer-fighting vaccine

In addition to these techniques The Ottawa Hospital’s Dr. Rebecca Auer has found that a cell vaccine, developed in the lab using an individual’s cancer cells combined with a cancer-fighting virus, could be effective in battling cancer. Once injected, this vaccine uses a triple-threat to attack the cancer.

Doctor speaking with a patient in her office at a hospital — Dr. Rebecca Auer, The Ottawa Hospital

First, the virus only infects and kills cancer cells, leaving healthy cells unscathed. Second, the virus produces a protein called interleukin-12, which boosts the immune system’s natural ability to fight the tumour. Third, as a result, the vaccine trains the immune system to recognize and fight off the same kind of tumour if it ever comes back.

Dr. Auer and her colleagues are developing the processes required to manufacture this personalized cell vaccine and plan to initiate a “first in human” clinical trial in 2020.

Lifesaving therapies: from idea to bedside

Today, cancer care is changing at an unprecedented pace. Many patients who, only a few years ago, had few to no treatment options are now being offered hope with treatments that are more targeted and personalized. We are seeing approvals for new cancer drugs grow at an almost exponential rate, while world-class research and clinical trials are being integrated into cutting-edge cancer care.

Over the next 15 years, Canadians will see a 40 percent increase in cancer diagnoses with almost one in two developing cancer in their lifetime. Our ability to translate research into patient therapies coupled with one of the best-equipped cancer centres in the country means we are well-positioned to face this challenge head-on.

Go inside the Biotherapeutics Manufacturing Centre at The Ottawa Hospital.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Biotherapeutics, Biotherapeutics, Biotherapeutics, Cancer, Immunotherapy, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research, World-Leading Research

OCTOBER 26, 2019 OTTAWA, ON – It was a sold-out night at The Ottawa Hospital Gala, presented by First Avenue Investment Counsel, which recognized three innovative researchers. The elegant ballroom of the Westin Hotel was transformed with exquisite décor and a delectable four-course meal, enjoyed by more than 700 guests. It also marked the final gala with Dr. Jack Kitts as President and CEO of The Ottawa Hospital, who will retire in 2020. Guests paid tribute to Dr. Kitts with a standing ovation for his dedication to providing compassionate and world-class care to the Ottawa community through his leadership since 2002.

The Ottawa Hospital Gala celebrated the transformational work of three researchers dedicated to improving care. Congratulations to this year’s three award winners:

Faizan Khan, recipient of the Worton Researcher in Training Award, recognized for his outstanding work on vein blood clots, including a recent British Medical Journal study establishing long-term risks and consequences of clot recurrence.

Dr. Marjorie Brand, recipient of the Chrétien Researcher of the Year Award, recognized for her groundbreaking discovery of how a blood stem cell decides whether to become a red blood cell or a platelet-forming cell.

Dr. Paul Albert, recipient of the Grimes Research Career Achievement Award, recognized for his leadership in Neuroscience, as well as his innovative work on what causes depression and how to treat it.

The Ottawa Hospital is recognized for its world-leading research that attracts internationally recognized scientists and clinicians from around the world. Tim Kluke, President and CEO of The Ottawa Hospital Foundation, emphasized that it’s corporate and individual philanthropic gifts, which make that a reality. “We are privileged to have the support of a generous community which is helping this city advance research to find new hope for patients now and in the future.”

First Avenue Investment Counsel returned as the presenting sponsor of The Ottawa Hospital Gala this year. Kash Pashootan, CEO and Chief Investment Officer at First Avenue Investment Counsel, said it’s a partnership that aligns perfectly. “Innovative research is a necessary investment in the future of health care in our community and we’re proud to fulfill our duty to The Ottawa Hospital. At First Avenue Investment Counsel, we advise families on all aspects of their financial picture including managing their assets to ensure their secure future for them and future generations. Together, we’re laying the building blocks for the future.”

About The Ottawa Hospital: 

The Ottawa Hospital is one of Canada’s largest learning and research hospitals, with more than 1,200 beds, 12,000 staff members and an annual budget of about approximately $1.3 billion.

The focus on learning and research helps to develop new and innovative ways to treat patients and improve care. As a multi-campus hospital affiliated with the University of Ottawa, specialized care is delivered to the eastern Ontario region and the techniques and research discoveries are adopted around the world. The hospital engages the community at all levels to support our vision for better patient care.

From the compassion of our people to the relentless pursuit of new discoveries, The Ottawa Hospital never stops seeking solutions to the most complex patient-centred care. For more information about The Ottawa Hospital, visit ohfoundation.ca.

Community generosity funds a second round of promising COVID-19 research projects

Harnessing cancer-fighting viruses to develop a COVID-19 vaccine

Creating a new mouse model to study COVID-19 lung disease

Studying the immune response of COVID-19 patients in the ICU

A balancing act: how to provide regular patient care amid the threat of COVID-19

Helping COVID-19 survivors stay healthy

World-first clinical trial aims to protect cancer patients from COVID-19

Support future projects

Using lab-grown human tissues to identify possible treatments

Stopping COVID-19 with behavioral science and artificial intelligence

Understanding the challenge of COVID-19 for Ottawa’s most vulnerable people

Mobile reporting of adverse events from a pandemic COVID-19 vaccine

Testing plasma from recovered COVID-19 patients as a possible treatment

Predicting COVID-19 in populations

Repurposing existing drugs and finding new ones

More inspiring projects

Calming the immune system in critically ill patients

Repurposing existing drugs and finding new ones

Learning from our COVID-19 patients and testing therapies

Working towards a vaccine

Putting preparedness to the test

Simulation exercises save lives

Community support essential

Mackenzie Daybutch

Hélène Létourneau-Donnelly

Macrina Valcin

Mary Ierullo

Dr. Rebecca Auer

Marion Crowe

Dr. Emily Gear

Dr. Kathleen Gartke

Dr. Julianna Tomlinson

Dr. Barabara Vanderhyden

A race against the clock

An uncertain future

Family ties

The race is on

A new Neuromuscular Centre

Zest for life

Hope despite aggressive skin cancer diagnosis

Discovery of a mass

Time to act

The next generation of treatment

Today, there is no sign of cancer

An unexpected early birth

BPD in Canada

Lack of treatment options

Clinical trial offers hope

First trial of its kind in Canada

A new beginning

Could cancer biotherapeutics be the next revolution in cancer treatment?

Helping the body recognize and destroy cancer

Infecting cancer cells with viruses

Cancer-fighting vaccine

Lifesaving therapies: from idea to bedside

More News